Stock Events

Stock Events

Race Oncology Limited 

$2.60
17
+$1.38+113.11% Friday 00:00

Statistics

Day High
0.83
Day Low
0.83
52W High
1.22
52W Low
0.83
Volume
3
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25AugExpected
Q2 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0.04
-0.02
-0.01
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-5.13MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas similar to Race Oncology, including cancer treatments, making it a direct competitor.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines in areas including cancer, competing in the same market as Race Oncology.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including oncology/hematology, which pits it against Race Oncology in the cancer treatment sector.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a global healthcare company that produces cancer drugs among other pharmaceuticals, directly competing with Race Oncology's offerings.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a research-based biopharmaceutical company with a broad range of cancer drugs, making it a competitor in the oncology market.
Novartis
NVS
Mkt Cap292.35B
Novartis AG engages in the research, development, manufacturing, and marketing of healthcare products, including oncology, directly competing with Race Oncology.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG specializes in pharmaceuticals and diagnostics with a strong focus on oncology, making it a competitor in the cancer treatment market.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca operates in the biopharmaceutical sector, focusing on the discovery and development of cancer treatments, competing in the same field as Race Oncology.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical segment, develops and sells oncology drugs, competing with Race Oncology in the healthcare market.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie is a research-driven biopharmaceutical company with a significant focus on oncology, making it a competitor in the cancer treatment market.

About

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.
Show more...
CEO
Dr. Peter M. Smith Ph.D.
Country
United States

Listings

MU
DE
FN3.MU
AU
AU
RAC.AU

0 Comments

Share your thoughts

FAQ

What is Race Oncology Limited stock price today?▼
The current price of RAONF is $2.60 USD — it has increased by +113.11% in the past 24 hours. Watch Race Oncology Limited stock price performance more closely on the chart.
What is Race Oncology Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange Race Oncology Limited stocks are traded under the ticker RAONF.
What is Race Oncology Limited revenue for the last year?▼
Race Oncology Limited revenue for the last year amounts to 0 USD.
What is Race Oncology Limited net income for the last year?▼
RAONF net income for the last year is -5.13M USD.
In which sector is Race Oncology Limited located?▼
Race Oncology Limited operates in the Health & Wellness sector.
When did Race Oncology Limited complete a stock split?▼
The last stock split for Race Oncology Limited was on November 29, 2023 with a ratio of 21:20.
Where is Race Oncology Limited headquartered?▼
Race Oncology Limited is headquartered in Sydney, United States.